Patents by Inventor Christopher R. Bebbington

Christopher R. Bebbington has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • VECTOR SYSTEM
    Publication number: 20080175819
    Abstract: The present invention provides a vector system comprising a nucleotide sequence coding for an antibody. In particular, the present invention relates to the use of such a vector system in a subject, where the nucleotide sequence is expressed in vivo to produce said antibody.
    Type: Application
    Filed: August 6, 2007
    Publication date: July 24, 2008
    Applicant: Oxford BioMedica (UK) Limited
    Inventors: Alan J. Kingsman, Christopher R. Bebbington, Miles W. Carroll, Fiona M. Ellard, Susan M. Kingsman, Kevin A. Myers
  • METHODS OF TREATING IDIOPATHIC THROMBOCYTOPENIA PURPURA USING A GM-CSF ANTAGONIST
    Publication number: 20080171038
    Abstract: The invention is based on the discovery that GM-CSF antagonists can be used for the treatment of Idiopathic Thrombocytopenia Purpura (ITP). Accordingly, the invention provides methods of administering a GM-CSF antagonist, e.g., a GM-CSF antibody, to a patient that has ITP and pharmaceutical compositions comprising such antagonists.
    Type: Application
    Filed: November 8, 2007
    Publication date: July 17, 2008
    Applicant: KaloBios Pharmaceuticals, Inc.
    Inventors: Christopher R. Bebbington, Geoffrey T. Yarranton
  • CD-10 activated prodrug compounds
    Patent number: 7304032
    Abstract: The compounds of the invention are modified forms of therapeutic agents. A typical prodrug compound of the invention comprises a therapeutic agent, an oligopeptide, a stabilizing group and, optionally, a linker group. The prodrug is cleavable by the CD10 enzyme. Methods of treatment using the prodrug and methods of designing a prodrug are also disclosed.
    Type: Grant
    Filed: December 22, 2004
    Date of Patent: December 4, 2007
    Assignee: Medarex, Inc.
    Inventors: Christopher R. Bebbington, Matthew H. Nieder, Pina M. Cardarelli, Sanjeev Gangwar, Lesley B. Pickford, Chin Pan
  • Vector system
    Patent number: 7276488
    Abstract: The present invention provides a vector system comprising a nucleotide sequence coding for an antibody. In particular, the present invention relates to the use of such a vector system in a subject, where the nucleotide sequence is expressed in vivo to produce said antibody.
    Type: Grant
    Filed: January 29, 2002
    Date of Patent: October 2, 2007
    Assignee: Oxford Biomedica (UK) Limited
    Inventors: Alan J. Kingsman, Christopher R. Bebbington, Miles W. Carroll, Fiona M. Ellard, Susan M. Kingsman, Kevin A. Myers
  • Tripeptide prodrug compounds
    Patent number: 7214663
    Abstract: The prodrug of the invention is a modified form of a therapeutic agent and comprises a therapeutic agent, an oligopeptide of three amino acids, a stabilizing group and, optionally, a linker group. The prodrug is cleavable by a trouase enzyme such as Thimet oligopeptidase. Also disclosed are methods of making and using the prodrug compounds.
    Type: Grant
    Filed: June 11, 2001
    Date of Patent: May 8, 2007
    Assignee: Medarex, Inc.
    Inventors: Christopher R. Bebbington, Vincent Dubois, Sanjeev Gangwar, Thomas J. Lobl, Matthew H. Nieder, Lesley B. Pickford, Andre Trouet, Geoffrey T. Yarranton
  • CD10-activated prodrug compounds
    Patent number: 6897034
    Abstract: The compounds of the invention are modified forms of therapeutic agents. A typical prodrug compound of the invention comprises a therapeutic agent, an oligopeptide, a stabilizing group and, optionally, a linker group. The prodrug is cleavable by the CD10 enzyme. Methods of treatment using the prodrug and methods of designing a prodrug are also disclosed.
    Type: Grant
    Filed: June 11, 2002
    Date of Patent: May 24, 2005
    Assignee: Medarex, Inc.
    Inventors: Christopher R. Bebbington, Matthew H. Nieder, Pina M. Cardarelli, Sanjeev Gangwar, Lesley B. Pickford, Chin Pan
  • CD10-activated prodrug compounds
    Publication number: 20040087497
    Abstract: The compounds of the invention are modified forms of therapeutic agents. A typical prodrug compound of the invention comprises a therapeutic agent, an oligopeptide, a stabilizing group and, optionally, a linker group. The prodrug is cleavable by the CD10 enzyme. Methods of treatment using the prodrug and methods of designing a prodrug are also disclosed.
    Type: Application
    Filed: June 11, 2002
    Publication date: May 6, 2004
    Inventors: Christopher R. Bebbington, Matthew H. Nieder, Pina M. Cardarelli, Sanjeev Gangwar, Lesley B. Pickford, Chin Pan
  • Tripeptide prodrug compounds
    Publication number: 20030181359
    Abstract: The prodrug of the invention is a modified form of a therapeutic agent and comprises a therapeutic agent, an oligopeptide of three amino acids, a stabilizing group and, optionally, a linker group. The prodrug is cleavable by a trouase enzyme such as Thimet oligopeptidase. Also disclosed are methods of making and using the prodrug compounds.
    Type: Application
    Filed: December 13, 2002
    Publication date: September 25, 2003
    Inventors: Christopher R. Bebbington, Vincent Dubois, Sanjeev Gangwar, Thomas J. Lobl, Matthew H. Nieder, Lesley B. Pickford, Andre Trouet, Geoffrey T. Yarranton
  • Vector system
    Publication number: 20030083290
    Abstract: The present invention provides a vector system comprising a nucleotide sequence coding for an antibody. In particular, the present invention relates to the use of such a vector system in a subject, where the nucleotide sequence is expressed in vivo to produce said antibody.
    Type: Application
    Filed: January 29, 2002
    Publication date: May 1, 2003
    Inventors: Alan J. Kingsman, Christopher R. Bebbington, Miles W. Carroll, Fiona M. Ellard, Susan M. Kingsman, Kevin A. Myers
  • Recombinant DNA expression vectors
    Patent number: 5591639
    Abstract: The invention provides expression vectors containing the promoter, enhancer and substantially complete 5'-untranslated region including the first intron of the major immediate early gene of human cytomegalovirus. Further vectors including the hCMV-MIE DNA linked directly to the coding sequence of a heterologous gene are described, Host cells transfected with the vectors and a process for producing heterologous polypeptides using the vectors and the use of the hCMV-MIE DNA for expression of a heterologous gene are also included within the invention.
    Type: Grant
    Filed: September 2, 1994
    Date of Patent: January 7, 1997
    Assignee: Celltech Ltd
    Inventor: Christopher R. Bebbington
  • Method for dominant selection in eucaryotic cells
    Patent number: 5122464
    Abstract: Recombinant DNA sequences which encode the complete amino acid sequence of a glutamine synthetase, vectors containing such sequences, and methods for their use, in particular as dominant selectable markers, for use in co-amplificiation of non-selected genes and in transforming host cell lines to glutamine independence.
    Type: Grant
    Filed: October 10, 1990
    Date of Patent: June 16, 1992
    Assignees: Celltech Limited, a British Company, The University Court of the University of Glasgow
    Inventors: Richard H. Wilson, Christopher R. Bebbington